Attorney Chelsey Youman, who represents Human Coalition, tells Morning Edition that despite 23 years of study and repeated reviews, the FDA has not fully accounted for possible complications. And the high court temporarily paused lower court rulings while setting the Friday deadline to decide whether to let any restrictions take effect.Īdvocates cite one study to counter a green light from FDAĪn attorney for an advocacy group that filed an amicus brief on behalf of parties suing for mifepristone restrictions argues that the drug declared "safe and effective" by the FDA is dangerous. Supreme Court to preserve access to mifepristone. It declared that the time had passed for challenging the original FDA approval, but it also tightened the agency's window for using the drug from 10 weeks, as approved in 2016, to seven weeks. Five days later, the 5th Circuit Court of Appeals narrowed Kacsmaryk's ruling. District Judge Thomas Rice, issued a contrary ruling directing federal authorities not to make any changes in mifepristone access in at least 17 states where Democrats had sued to protect availability. Within minutes, a judge in Washington state, U.S. District Judge Matthew Kacsmaryk imposed a nationwide ban, saying the Food and Drug Administration (FDA) had improperly approved mifepristone 23 years ago. Mifepristone was called into question on April 7, when U.S. It is also used in miscarriage management. Anti-abortion advocates demonstrate against abortion pills outside the Supreme Court on Friday.Īctivists on both sides of the abortion issue are awaiting a Supreme Court decision on the medication mifepristone, used in more than half of the abortions in the U.S.
0 Comments
Leave a Reply. |